Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

(2010) J. B. Buse et al.   DIABETES CARE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

(2010) D. W. Porter et al.   DIABETES OBESITY & METABOLISM

Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

(2010) Baptist Gallwitz   DRUG SAFETY

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

(2010) S. S. Engel et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

The evolving place of incretin-based therapies in type 2 diabetes

(2010) Baptist Gallwitz   PEDIATRIC NEPHROLOGY

Preface

(2009) Michael A. Nauck   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus

(2009) Tina Vilsbøll et al.   BIODRUGS

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: A randomized, placebo-controlled, single-blind, dose-escalation, crossover study

(2009) Jaret Malloy et al.   CLINICAL THERAPEUTICS

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

(2009) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

(2009) M. A. Nauck et al.   DIABETES CARE

Incretin-Based Therapies: Viewpoints on the way to consensus

(2009) Michael. A. Nauck et al.   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies

(2009) Bernard Zinman   DIABETES OBESITY & METABOLISM

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

(2009) J. H. Best et al.   DIABETIC MEDICINE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus

(2009) S. Matthaei et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue

(2009) Kjetil Retterstøl   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Update on Nonautoimmune Diabetes in Children

(2009) Philip Zeitler   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies

(2009) Kiwon Ban et al.   Journal of the American Society of Hypertension

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Molecular Pharmacology of Promiscuous Seven Transmembrane Receptors Sensing Organic Nutrients

(2009) P. Wellendorph et al.   MOLECULAR PHARMACOLOGY

New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus

(2009) Vandana S Raman et al.   PEDIATRIC RESEARCH

Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits

(2009) Michael Nauck et al.   POSTGRADUATE MEDICINE

Insights from the Liraglutide Clinical Development Program—the Liraglutide Effect and Action in Diabetes (LEAD) Studies

(2009) Janet B. McGill   POSTGRADUATE MEDICINE

Effects of Intravenous Glucagon-Like Peptide-1 on Glucose Control and Hemodynamics After Coronary Artery Bypass Surgery in Patients With Type 2 Diabetes

(2008) Karsten Müssig et al.   AMERICAN JOURNAL OF CARDIOLOGY

Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010

(2008) U. Werner   ANNALES D ENDOCRINOLOGIE

The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure

(2008) Hertzel C. Gerstein   ARCHIVES OF INTERNAL MEDICINE

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

(2008) T. Vilsbøll et al.   DIABETIC MEDICINE

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Exenatide and Rare Adverse Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gastric distention activates satiety circuitry in the human brain

(2007) Gene-Jack Wang et al.   NEUROIMAGE